Q&A: Can oncolytic viruses make a comeback? Experts dissect clinical failures and outline path forward
In the eight years since the FDA first approved an oncolytic virus as a cancer therapy, developers have been striving — and largely failing — to bring next-gen treatments to the market. But a new wave could be upon us.
Can oncolytic viruses make a comeback? That was a topic of a recent panel hosted by Endpoints News. Our guests were Paul Peter Tak, a former GSK exec who’s now CEO of viral immunotherapy developer Candel Therapeutics; Howard Kaufman, the president and CEO of Ankyra Therapeutics and a longtime researcher of oncolytic viruses; and Adina Pelusio, the senior vice president of clinical operations at KaliVir Immunotherapeutics, who has more than 20 years of experience leading clinical trials for these therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.